Stockscreener 앱 받기
6.175
2.40%
0.145
전일 마감가:
$6.03
열려 있는:
$5.96
하루 거래량:
64,287
Relative Volume:
0.28
시가총액:
$70.95M
수익:
$1.54M
순이익/손실:
$-38.70M
주가수익비율:
-1.3223
EPS:
-4.67
순현금흐름:
$-36.86M
1주 성능:
+6.47%
1개월 성능:
+7.39%
6개월 성능:
-65.05%
1년 성능:
-84.26%
1일 변동 폭
$5.90
$6.355
1주일 범위
$5.73
$6.355
52주 변동 폭
$4.64
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
명칭
Corbus Pharmaceuticals Holdings Inc
전화
617-963-0103
주소
500 RIVER RIDGE DRIVE, NORWOOD, MA
CRBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
6.1501 | 70.95M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.75 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.78 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.54 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.40 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.75 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 개시 | Wedbush | Outperform |
| 2024-07-22 | 재개 | H.C. Wainwright | Buy |
| 2024-06-26 | 개시 | B. Riley Securities | Buy |
| 2024-06-03 | 재확인 | Oppenheimer | Outperform |
| 2024-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-08 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-03-26 | 개시 | Nomura | Buy |
| 2019-04-05 | 개시 | Jefferies | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-01-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 개시 | H.C. Wainwright | Buy |
| 2018-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2018-10-24 | 개시 | B. Riley FBR | Buy |
| 2018-01-19 | 개시 | Raymond James | Outperform |
| 2017-12-14 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 재확인 | Noble Financial | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-03-30 | 재확인 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-11 | 재확인 | Noble Financial | Buy |
모두보기
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
(CRBP) Trading Report - news.stocktradersdaily.com
We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth - Yahoo Finance
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP stock touches 52-week low at $4.64 amid sharp annual decline - Investing.com
CRBP stock touches 52-week low at $4.64 amid sharp annual decline By Investing.com - Investing.com South Africa
Where are the Opportunities in (CRBP) - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Target Price at $59.13 - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles Schwab Investment Management Inc. Purchases 4,239 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP Stock Plummets to 52-Week Low of $5.65 Amid Market Turbulence By Investing.com - Investing.com South Africa
Corbus begins Phase 1 trial for new obesity treatment CRB-913 By Investing.com - Investing.com South Africa
CRBP Stock Plummets to 52-Week Low of $5.65 Amid Market Turbulence - Investing.com
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity - Quantisnow
Corbus begins Phase 1 trial for new obesity treatment CRB-913 - Investing.com
Corbus Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Next-Gen Obesity Drug Shows 50x Better Safety Profile Than Previous Treatments as Clinical Trials Begin - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
(CRBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Corbus Pharmaceuticals to reduce board size post-annual meeting By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Corbus Pharmaceuticals to reduce board size post-annual meeting - Investing.com
Corbus Pharmaceuticals Announces Board Member Departure - TipRanks
CRBP stock touches 52-week low at $5.9 amid steep annual decline - Investing.com Australia
CRBP stock touches 52-week low at $5.9 amid steep annual decline By Investing.com - Investing.com South Africa
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) - Yahoo Finance
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) - Yahoo Finance
Corbus Pharmaceuticals appoints new COO By Investing.com - Investing.com Australia
Corbus Pharmaceuticals Appoints Ian Hodgson as COO - TipRanks
Corbus Pharmaceuticals appoints new COO - Investing.com
B. Riley Lifts Earnings Estimates for Corbus Pharmaceuticals - Defense World
HC Wainwright Issues Positive Estimate for CRBP Earnings - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target Cut to $53.00 by Analysts at Jefferies Financial Group - MarketBeat
Lifesci Capital Has Optimistic Outlook of CRBP Q1 Earnings - Defense World
What is B. Riley’s Forecast for CRBP Q1 Earnings? - Defense World
Wedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns “Buy” Rating from HC Wainwright - Defense World
CRBP stock touches 52-week low at $6.53 amid sharp annual decline - Investing.com Australia
Corbus Pharmaceuticals Holdings Inc (CRBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
0.11%
자본화:
|
볼륨(24시간):